Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.20)
# 2,835
Out of 4,966 analysts
112
Total ratings
47.76%
Success rate
-5.19%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCAT Health Catalyst | Maintains: In-Line | $3 → $4 | $3.39 | +17.99% | 8 | Aug 28, 2025 | |
| HSIC Henry Schein | Upgrades: Outperform | $83 | $69.58 | +19.29% | 1 | Aug 26, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $200 → $190 | $148.78 | +27.71% | 9 | Aug 13, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $5 → $7 | $9.85 | -28.93% | 9 | Aug 8, 2025 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $60 | $56.08 | +6.99% | 1 | Aug 6, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $300 | $277.99 | +7.92% | 6 | Jul 25, 2025 | |
| TDOC Teladoc Health | Maintains: In-Line | $7 → $8 | $7.73 | +3.49% | 4 | Jul 9, 2025 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $28 | $23.04 | +21.53% | 4 | Jul 9, 2025 | |
| NVST Envista Holdings | Maintains: Outperform | $19 → $23 | $21.18 | +8.59% | 4 | Jul 9, 2025 | |
| MCK McKesson | Maintains: Outperform | $760 → $800 | $686.64 | +16.51% | 6 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $180 | $190.81 | -5.67% | 6 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $1.28 | +134.38% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $70 | $67.94 | +3.03% | 8 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $200 | $141.96 | +40.88% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $175 → $180 | $181.64 | -0.90% | 3 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $73.15 | -11.14% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $14.30 | +39.86% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $37.88 | -4.96% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.11 | +413.70% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.87 | +287.60% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.26 | +386.73% | 2 | Jan 4, 2022 |
Health Catalyst
Aug 28, 2025
Maintains: In-Line
Price Target: $3 → $4
Current: $3.39
Upside: +17.99%
Henry Schein
Aug 26, 2025
Upgrades: Outperform
Price Target: $83
Current: $69.58
Upside: +19.29%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $200 → $190
Current: $148.78
Upside: +27.71%
Fortrea Holdings
Aug 8, 2025
Maintains: In-Line
Price Target: $5 → $7
Current: $9.85
Upside: -28.93%
Hinge Health
Aug 6, 2025
Maintains: Outperform
Price Target: $50 → $60
Current: $56.08
Upside: +6.99%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $285 → $300
Current: $277.99
Upside: +7.92%
Teladoc Health
Jul 9, 2025
Maintains: In-Line
Price Target: $7 → $8
Current: $7.73
Upside: +3.49%
Privia Health Group
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $23.04
Upside: +21.53%
Envista Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $21.18
Upside: +8.59%
McKesson
Jul 9, 2025
Maintains: Outperform
Price Target: $760 → $800
Current: $686.64
Upside: +16.51%
Jul 9, 2025
Maintains: Outperform
Price Target: $170 → $180
Current: $190.81
Upside: -5.67%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $1.28
Upside: +134.38%
Jul 9, 2025
Upgrades: Outperform
Price Target: $50 → $70
Current: $67.94
Upside: +3.03%
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $141.96
Upside: +40.88%
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $181.64
Upside: -0.90%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $73.15
Upside: -11.14%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $14.30
Upside: +39.86%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $37.88
Upside: -4.96%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.11
Upside: +413.70%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.87
Upside: +287.60%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.26
Upside: +386.73%